BNTX - BioNTech GAAP EPS of Euro9.26 beats by Euro1.51 revenue of Euro4.28B beats by Euro420M
2023-03-27 06:54:11 ET
- BioNTech press release ( NASDAQ: BNTX ): Q4 GAAP EPS of €9.26 beats by €1.51 .
- Revenue of €4.28B (-22.6% Y/Y) beats by €420M .
- Expanded and advanced oncology pipeline to 20 programs in 24 ongoing clinical trials including five ongoing randomized Phase 2 clinical trials; multiple trials with registrational potential expected to be initiated in 2023 and 2024.
- The company expects COVID-19 vaccine revenues of ~€5B for FY2023.
- BNTX expects to authorize a share repurchase program of up to $0.5B during the remainder of 2023.
For further details see:
BioNTech GAAP EPS of €9.26 beats by €1.51, revenue of €4.28B beats by €420M